

## Appendix: Patient Group Conflict of Interest Declaration

To maintain the objectivity and credibility of the CADTH CDR and pCODR programs, all participants in the drug review processes must disclose any real, potential, or perceived conflicts of interest. This Patient Group Conflict of Interest Declaration is required for participation. Declarations made do not negate or preclude the use of the patient group input. CADTH may contact your group with further questions, as needed.

1. Did you receive help from outside your patient group to complete this submission? If yes, please detail the help and who provided it. **Yes.** Target Ovarian Cancer in the U.K. provided a copy of their patient submission to the Scottish Medicines Consortium consultation on niraparib in April 2018.
2. Did you receive help from outside your patient group to collect or analyze data used in this submission? If yes, please detail the help and who provided it. **No**
3. List any companies or organizations that have provided your group with financial payment over the past two years AND who may have direct or indirect interest in the drug under review.

Company	Check Appropriate Dollar Range			
	\$0 to 5,000	\$5,001 to 10,000	\$10,001 to 50,000	In Excess of \$50,000
March 2018 – AstraZeneca. Sponsorship for Canadian Conference on Ovarian Cancer Research		X		
April 2018 – Hoffman LaRoche. Sponsorship for Canadian Conference on Ovarian Cancer Research	X			
April 2018 – AstraZeneca. Sponsorship for Love HER		X		
May 2018 – AstraZeneca. Program funding				X
November 2018 – AstraZeneca. \$2K honorarium and travel expenses for Marilyn Sapsford to attend the AZ Niraparib Ovarian Cancer National Advisory Board Meeting in Montreal	X			
February 2019 – AstraZeneca. Program funding				X
April 2019 – AstraZeneca. Sponsorship Lady Ball Vancouver		X		
May 2019 – AstraZeneca. Sponsorship Lady Ball Calgary, Charlottetown, Halifax and program funding			X	
June 2019 – GSK. Honorarium for Elisabeth Baugh for attendance at meeting regarding Patient Support Program	X			
August 2019 – AstraZeneca. Honorarium and travel for Elisabeth Baugh to attend Patient Advisory Board meeting in Boston	X			
October 2019 – AstraZeneca. Research/Education Workshop	X			
November 2019 – AstraZeneca. Honorarium for Alicia Tone to attend the AZ Ovarian Cancer National Advisory Board Meeting in Montreal	X			
December 2019. GSK. Program funding				X
March 2020. AstraZeneca. Program funding				X

I hereby certify that I have the authority to disclose all relevant information with respect to any matter involving this patient group with a company, organization, or entity that may place this patient group in a real, potential, or perceived conflict of interest situation.

**Name:** Alicia Tone, PhD

**Position:** Scientific Advisor

**Patient Group:** Ovarian Cancer Canada

**Date:** September 23, 2020